<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757692</url>
  </required_header>
  <id_info>
    <org_study_id>OZM-011</org_study_id>
    <nct_id>NCT00757692</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.</brief_title>
  <official_title>A Phase II Randomised Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose To define the efficacy, tolerability and safety of Vandetanib in combination with&#xD;
      bicalutamide in patients with chemotherapy naive hormone refractory prostate cancer&#xD;
&#xD;
      Hypothesis There will be a PSA response when Vandetanib is given in combination with&#xD;
      Bicalutamide in Chemotherapy Naive Hormone refractory prostate cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the advent of PSA surveillance, many patients diagnosed with hormone refractory disease,&#xD;
      have PSA rising disease only, are asymptomatic, with no evidence of metastatic disease. There&#xD;
      is no standard of care in this patient population. A standard treatment in this population&#xD;
      has been the addition of a non-steroidal anti androgen such as bicalutamide. PSA response&#xD;
      rate (defined as a 50% decrease) have been reported in 20% range with bicalutamide.&#xD;
&#xD;
      Even in patients with hormone refractory prostate cancer (HRPC) and metastases that have no&#xD;
      cancer related symptoms, initiation of chemotherapy is controversial given the palliative&#xD;
      nature of chemotherapy and potential for serious toxicity.&#xD;
&#xD;
      These patients are generally well enough to to undergo trials of novel agents and achieve&#xD;
      adequate drug exposure, such that any cytostatic effect will be apparent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response</measure>
    <time_frame>Continuous to end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to over all progression</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of treatment related toxicity</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bicalutamide at 50 mg will be administered orally, daily and continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Bicalutamide at 50 mg will be administered orally, daily and continuously.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a pathological diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
          -  Patients must have biochemically recurrent disease or metastatic disease that is&#xD;
             asymptomatic or minimally symptomatic (total daily morphine dose &lt; 30mg.day) for which&#xD;
             no curative therapy exists.&#xD;
&#xD;
          -  Patients must have documented evidence od PSA progression while receiving androgen&#xD;
             ablative therapy (i.e. must be hormone refractory). Progression is defined as the&#xD;
             development of new metastatic lesions, or rising PSA defined as at least two rises in&#xD;
             PSA at least 1 week apart. If the second PSA is not rising, a thrid PSA is required to&#xD;
             show further increase; if not, a subsequent level must show further increase. The&#xD;
             third (or subsequent) PSA confirming progression must be within 2 weeks of&#xD;
             randomization.&#xD;
&#xD;
          -  The PSA must be =&gt; 2ug/L at the time of study entry.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Age =&gt;18 years&#xD;
&#xD;
          -  Patients must have a life expectancy of at least 12 weeks&#xD;
&#xD;
          -  No Prior chemotherapy is permissible for hormone refractory disease. Chemotherapy may&#xD;
             have been received in a neoadjuvant or adjuvant setting provided it was given 12&#xD;
             months prior to registration.&#xD;
&#xD;
          -  Hormone Therapy&#xD;
&#xD;
               -  Prior hormone therapy in the form of either medical or surgical castration is&#xD;
                  required. If the patient is receiving medical androgen abalation a castrate level&#xD;
                  of testosterone (1.7nmol/L) must be present. Therapy with LHRH agonist must&#xD;
                  continue for those prostate cancer patients already receiving this treatment at&#xD;
                  the time of registration. If the patients has discontinued the LHRH agonist, this&#xD;
                  must be restarted and a castrate level of testosterone must be present.&#xD;
&#xD;
               -  Prior use of nonsteroidal antiandrogens (including bicalutamide) is permitted but&#xD;
                  must have been discontinued 6 weeks prior to registration.&#xD;
&#xD;
          -  Prior external beam radiation is permitted provided a minimum of 4 weeks has elapsed&#xD;
             between the last dose and registration in the trial. Exceptions will be made for&#xD;
             limited field, single fraction palliative radiation to bone.&#xD;
&#xD;
          -  No concurrent treatment with steriods unless steriods have been ingested for 4 weeks&#xD;
             prior to commencing study at a dose of less than or equal to an equivalent of&#xD;
             prednisone 20mg per day.&#xD;
&#xD;
          -  No concurrent experimental trial medication is permitted. No prior use of VEGF/VEGFR&#xD;
             or EGFR targeting agents for hormone refractory disease is permitted.&#xD;
&#xD;
          -  Laboratory Requirements- within 7 calendar days prior to registration Hematology:&#xD;
             haemoglobin &gt;= 100g/L neutrophils &gt;=1.5 x 10(9)/L Platelets &gt;=100 x 10(9)/L INR =&lt;1.5&#xD;
             x upper limit of normal Biochemistry: AST, ALT = &lt;1.5 x upperlimit of normal Bilirubin&#xD;
             &lt;1.5 x upper limit of normal Serum creatinine &lt;1.5 x upper limit of normal&#xD;
&#xD;
          -  Baseline QTc (Bazett's) &lt;480msec determined by the average of a least 3 consecutive&#xD;
             electrocardiograms (ECG) taken within 5-10 mins of each other.&#xD;
&#xD;
          -  Patient consent must be obtained according to local institutional and/or University&#xD;
             Research and Ethic Board (REB) requirements.&#xD;
&#xD;
          -  Patients must be accessible for treatment and follow up.&#xD;
&#xD;
          -  Protocol treatment is to begin within 7 calendar days of patient registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of other invasive malignancy, except:adequately treated non&#xD;
             melanoma skin cancer or other solid tumors curatively treated with no evidence of&#xD;
             disease for 3 years.&#xD;
&#xD;
          -  Patients with known brain metastases or leptomemingeal disease are excluded from this&#xD;
             clinical trial because of their poor prognosis and because they often develop&#xD;
             progressive neurological dysfunction that would confound the evaluation of nerologic&#xD;
             and other adverse events.&#xD;
&#xD;
          -  History of allergic reactions and/or sensitivity attributed to compounds of similar&#xD;
             chemical or biological composition to Vandetanib or other agents used in the study.&#xD;
&#xD;
          -  Other serious intercurrent illness or medical condition that might be aggravated by&#xD;
             protocol treatment including;myocardial infarction within 6 months prior to study&#xD;
             entry, congestive heart failure, unstable angina,cardiomyopathy, unstable ventricular&#xD;
             arrhythmias,OTc (Bazett's) &gt;480msec Uncontrolled hypertension (systolic &gt;160, diatolic&#xD;
             &gt;100) Uncontrolled psychotic disorders, serious infections,peptic ulcer&#xD;
             disease,history of bleeding diathesis&#xD;
&#xD;
          -  Upper gasrtointerstinal or other conditions that would preclude compliance with oral&#xD;
             medication&#xD;
&#xD;
          -  Patients with immune deficiency are at increased risk of lethal infections when&#xD;
             treated with Marrow-suppressive therapy. Therefore, HIV positive patients receiving&#xD;
             combination ant-retroviral therapy are excluded from study because of possible risk of&#xD;
             lethal infection and additionally because of the possible pharmacokinetic interactions&#xD;
             with Vandetanib. Appropriate studies will be undertaken in patients receiving&#xD;
             combination anti-retroviral therapy when indicated.&#xD;
&#xD;
          -  Patients who require escalating amounts of narcotic therapy to control pain e.g.&#xD;
             morphine equivalent dose &gt;30mg/day) since these patients would more appropriately be&#xD;
             offered systemic chemotherapy&#xD;
&#xD;
          -  Patients who require therapeutic anticoagulation with warfarin.&#xD;
&#xD;
          -  Patients who require the following medication:concomittant use of warfarin, Class 1A&#xD;
             antiarrythmics (e.g., quinidine, procainamide, disopyramide) Class&#xD;
&#xD;
             1C antiarrhythmics (e.g.,flecainide, propafenone), Class III antiarrhythmics (e.g.,&#xD;
             amiodarone, sotalol, ibutilide), antipsychotics (e.g., thioridazine, chlorpromazine,&#xD;
             pimozide, haloperidol, droperidol), tri/tetracyclic antidepressants (e.g.,&#xD;
             amitriptyline, imipramine, maprotiline), ketoconazole, antiepileptics and macrolide&#xD;
             antibiotics.&#xD;
&#xD;
          -  Patients who cannot stop ingestion of grapefruit/juice.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Chi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BC Cancer Agency - Vancouver Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Cancer Agency - Centre for Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vandetanib (ZD6474)</keyword>
  <keyword>Hormone</keyword>
  <keyword>Refractory</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Na√Øve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

